Aaron Lee, MD, an associate professor of ophthalmology at University of Washington, describes how artificial intelligence (AI) is used in ophthalmology now and how it could be utilized in the future.
In the future, we're going to see artificial intelligence algorithms integrated into almost every aspect of clinical ophthalmology, said Aaron Lee, MD, an associate professor of ophthalmology at University of Washington. Lee’s session "How Will AI Change My Practice in the Next 5 Years?" was presented at the American Academy of Ophthalmology's 2021 conference.
Transcript:
Can you introduce yourself and explain your work?
Sure, so my name is Aaron Lee. I am an associate professor of ophthalmology at the University of Washington in Seattle. I'm a vitreoretinal surgeon by training and I lead a large lab in what we call computational ophthalmology. We have about 15 people who are working on translating novel computational ideas into ophthalmology.
What are some ways you predict artificial intelligence (AI) will be integrated into ophthalmology practices in the coming years?
That's a great question and it's one that I feel like is going to evolve and change over time. It's really hard to tell exactly how AI is going to play a role in the coming years. Right now, AI is already integrated into our clinical workflows with diabetic retinopathy screening with the 2 FDA-approved algorithms. They are already being deployed and used in the United States. I think more and more, we're going to start to see AI algorithms being integrated into almost every aspect of clinical ophthalmology. How quickly that's going to happen is anybody's to guess. The rate limiting factor tends to be more of the regulatory hurdles that need to be overcome before they can be safely deployed in the field.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Targeted Treatment May Improve Outcomes in IDH1-Mutated MDS
January 13th 2025A pair of abstracts presented at the 2024 American Society of Hematology (ASH) Annual Meeting & Exhibition suggest that IDH1-targeted treatment may improve survival among patients with myelodysplastic syndromes (MDS) with the mutation.
Read More